We are live on
!
Find out more
SVCM
Saturn V Capital Management Portfolio holdings
AUM
$552M
1-Year Est. Return
551.78%
This Fund
S&P 500
This Quarter
Est. Return
+40.7%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$22.3M
(+9.3%)
Cap. Flow
-$22.8M
Cap. Flow
% of AUM
-8.73%
Top 10 Holdings %
Top 10 Hldgs %
74.44%
Holding
26
New
6
Increased
7
Reduced
10
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$19.2M |
| 2 |
MRUS
Merus
MRUS
|
+$8.16M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$7.25M |
| 4 |
Disc Medicine
IRON
|
+$3.32M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$3.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$14.4M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$12.8M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$10.4M |
| 4 |
Biogen
BIIB
|
+$7.91M |
| 5 |
Cogent Biosciences
COGT
|
+$7.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$10.9B
| $37.4M | 14.32% |
448,144
-47,024
| -9% | -$1.7M |
|
|
2
Crinetics Pharmaceuticals
CRNX
$8.87B
| $28M | 10.72% |
787,132
-339,447
| -30% | -$10.4M |
|
|
KALV
3
DELISTED
KalVista Pharmaceuticals
KALV
| $22.1M | 8.48% |
1,807,563
-2,683
| -0.1% | -$24.4K |
|
|
4
argenx
ARGX
$56.2B
| $19.5M | 7.45% |
51,175
+41,101
| +408% | +$19.2M |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $17.7M | 6.78% |
750,250
-374,209
| -33% | -$6.66M |
|
6
Ascendis Pharma A/S
ASND
$16.7B
| $16.6M | 6.35% |
131,759
+19,286
| +17% | +$1.92M |
|
|
7
Amylyx Pharmaceuticals
AMLX
$2.04B
| $16.2M | 6.19% |
1,099,268
+213,125
| +24% | +$3.27M |
|
8
AnaptysBio
ANAB
$1.61B
| $14.2M | 5.45% |
664,276
+87,175
| +15% | +$1.5M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.7B
| $11.5M | 4.4% |
119,188
+9,503
| +9% | +$841K |
|
10
Syndax Pharmaceuticals
SNDX
$1.86B
| $11.2M | 4.29% |
518,799
-289,170
| -36% | -$4.45M |
|
|
MRUS
11
DELISTED
Merus
MRUS
| $10.7M | 4.1% |
389,333
+349,267
| +872% | +$8.16M |
|
|
ITOS
12
DELISTED
iTeos Therapeutics
ITOS
| $9.07M | 3.47% |
828,232
-166,524
| -17% | -$1.65M |
|
|
APLS
13
DELISTED
Apellis Pharmaceuticals
APLS
| $8.56M | 3.27% |
+142,927
| New | +$7.25M |
|
|
14
Biogen
BIIB
$29.8B
| $8.4M | 3.22% |
32,469
-32,207
| -50% | -$7.91M |
|
|
ATXS
15
DELISTED
Astria Therapeutics
ATXS
| $7.61M | 2.91% |
990,663
-228,430
| -19% | -$1.26M |
|
|
MORF
16
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $6.13M | 2.35% |
212,343
+75,600
| +55% | +$1.8M |
|
|
17
Cogent Biosciences
COGT
$6.9B
| $4.45M | 1.7% |
756,681
-1,018,734
| -57% | -$7.81M |
|
|
18
Disc Medicine
IRON
$2.85B
| $3.74M | 1.43% |
+64,784
| New | +$3.32M |
|
|
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
| $2.84M | 1.09% |
+199,973
| New | +$2.27M |
|
20
Alnylam Pharmaceuticals
ALNY
$37.7B
| $1.98M | 0.76% |
+10,327
| New | +$1.76M |
|
21
Phathom Pharmaceuticals
PHAT
$950M
| $1.46M | 0.56% |
+160,075
| New | +$1.38M |
|
22
Jasper Therapeutics
JSPR
$22.2M
| $1.09M | 0.42% |
138,622
-80
| -0.1% | -$537 |
|
|
AMAM
23
DELISTED
Ambrx Biopharma Inc
AMAM
| $752K | 0.29% |
+52,781
| New | +$600K |
|
24
BioCryst Pharmaceuticals
BCRX
$2.49B
| – | – |
-982,458
| Closed | -$6.96M |
|
|
25
Sarepta Therapeutics
SRPT
$1.73B
| – | – |
-118,401
| Closed | -$14.4M |
|
Similar funds
LF
SIAP
DCM
TC
BT
CA
IQI
TPA
Saturn V Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Saturn V Capital Management held 26 positions worth $261M, up 9.3% from $239M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Saturn V Capital Management withdrew a net $22.8M in Q4 2023, closing 3 positions and reducing 10 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $14.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Saturn V Capital Management opened a new position in Apellis Pharmaceuticals worth $8.56M.
- Saturn V Capital Management's largest Q4 2023 buy was Apellis Pharmaceuticals: 142,927 shares worth $8.56M.
- Saturn V Capital Management added most to argenx in Q4 2023, an estimated $19.2M increase.
- Saturn V Capital Management's biggest Q4 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $10.4M.
- Saturn V Capital Management fully exited Sarepta Therapeutics in Q4 2023, selling an estimated $14.4M.
- Saturn V Capital Management's ten largest holdings make up 74% of its $261M portfolio in Q4 2023.
- Saturn V Capital Management opened 6 new positions and closed 3 in Q4 2023.
- Saturn V Capital Management's portfolio value rose 9.3% quarter-over-quarter to $261M.
Based on Saturn V Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.